Search

everythinglearnresearchcommunity

for

Search:↓

A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.

Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.

Hair loss in male pattern baldness involves muscle degeneration and increased scalp fat.

Behçet's Disease may be caused by genetic and environmental factors leading to abnormal immune responses, and stress management and new treatments could improve patient outcomes.

The arrector pili muscle might play a role in hair loss and needs more research to understand its impact.

Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.

Injecting alpha-melanocyte-stimulating hormone in mice improved skin healing and reduced scarring.

Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.

Cell-based therapies show promise for treating Limbal Stem Cell Deficiency but need more research.

Early hair loss may indicate prostate issues.

Gene therapy, especially using atoh1, shows promise for creating functional sensory hair cells in the inner ear, but dosing and side effects need to be managed for clinical application.

The regenerative solution, tSVF, is a safe and effective treatment for various conditions like aged skin, scars, wounds, and more, but more research is needed to find the best way to use it.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

Scientists made skin stem cells from other human cells with over 97% efficiency, which could help treat skin conditions.

Alfredo Rebora suggested a new, easier way to classify hair loss in Telogen Effluvium, adding a type possibly related to autoimmune diseases.

Some diseases can improve the outcomes of other diseases, leading to new treatment possibilities.

PRP shows promise for improving facial wrinkles, skin elasticity, and hair growth, but more research is needed to standardize its use and understand its effects.

Substance from human umbilical cord blood cells promotes hair growth.

Moderately high prolactin levels do not cause hair loss in women.

Anti-cancer treatments can cause reversible hair loss, skin sensitivity, pigmentation changes, nail damage, and skin reactions, with a need for more research on managing these side effects.

Both human and animal-derived small extracellular vesicles speed up skin healing equally well.

The paper suggests improving diagnosis and treatment of telogen effluvium but does not recommend a new classification system.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Effective treatments for spinal and bulbar muscular atrophy are not yet available; more research is needed.

A new therapy sped up wound healing and reduced scarring in diabetic rats.

Metabolic syndrome linked to urinary symptoms; hair loss not significant.

New treatments and early diagnosis methods for permanent hair loss due to scar tissue are important for managing its psychological effects.

Finasteride and dutasteride are effective for long-term treatment of enlarged prostates but have sexual side effects and a risk of high-grade prostate cancer.

α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.